Table 2.
IFNL3 polymorphisms and steatosis in chronic hepatitis C
| No. of patients | Study design | HCV genotype | IFNL3 SNP | Results | Ethnicity | Ref. |
| 1604 | Retrospective | HCV-1 | rs12979860 | CC genotype associated with higher pretreatment LDL-C levels and less frequent hepatic steatosis | Caucasians | 46 |
| 145180 | Retrospective analysis of two Independent cohorts: (1) (antifibrotic) Study cohort; (2) Duke cohort | HCV-1 | rs12979860 | CC genotype associated with less hepatic steatosis | 122 (84.1%) Caucasians130 (72.2%) Caucasians | 47 |
| 434 | multi-center, Retrospective | HCV-1 | rs12979860 | CC genotype associated with less frequent hepatic steatosis | Caucasians | 48 |
| 202 | Prospective | HCV-1: 181 (89.6%) | rs12979860 | CC genotype associated with less frequent hepatic steatosis | Caucasians | 49 |
| HCV-4: 21 (10.4%) | ||||||
| 153 | Retrospective | HCV-1b | rs8099917 | TT genotype associated with less hepatic steatosis (vesicular and clear cell changes) | Japanese | 50 |
| 626 | Retrospective analysis of the Swiss Hepatitis C Cohort Study | Non-HCV-3 | rs12980275 | G associated with less hepatic steatosis only in non-HCV-3 | Caucasians | 51 |
| 122 | Retrospective | HCV-1b | rs8099917 | No association with hepatic steatosis | Japanese Mongolian | 52 |
| 445 | Retrospective | HCV-1: 303 (68.1%) | rs12979860 | No association with hepatic steatosis | Caucasian | 53 |
| HCV-2: 13 (2.9%) | ||||||
| HCV-3: 82 (18.4%) | ||||||
| HCV-4: 47 (10.6%) |
HCV: Hepatitis C virus; LDL-C: Low-density lipoprotein cholesterol.